Leavell Investment Management Inc. Has $1.05 Million Holdings in Pfizer Inc. $PFE

Leavell Investment Management Inc. decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 12.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 43,198 shares of the biopharmaceutical company’s stock after selling 6,198 shares during the quarter. Leavell Investment Management Inc.’s holdings in Pfizer were worth $1,047,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. GKV Capital Management Co. Inc. bought a new position in Pfizer during the 1st quarter worth approximately $27,000. Curio Wealth LLC increased its position in shares of Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,098 shares in the last quarter. Bayforest Capital Ltd bought a new position in Pfizer during the first quarter worth about $28,000. North Capital Inc. acquired a new position in Pfizer in the first quarter valued at about $28,000. Finally, Harbor Asset Planning Inc. bought a new stake in shares of Pfizer in the second quarter worth about $29,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Performance

PFE opened at $24.79 on Monday. The business’s 50-day simple moving average is $24.87 and its 200 day simple moving average is $24.20. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $29.17. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The firm has a market capitalization of $140.92 billion, a PE ratio of 13.18, a PEG ratio of 0.82 and a beta of 0.55.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

Analyst Ratings Changes

Several equities analysts recently issued reports on PFE shares. UBS Group reiterated a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research report on Wednesday, October 1st. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research report on Saturday. Morgan Stanley cut their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday, October 10th. Bank of America lifted their price target on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Finally, Citigroup increased their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average target price of $28.13.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.